English
Back
Download
Log in to access Online Inquiry
Back to the Top

Truist analyst Srikripa Devarakonda views the recent weaknes...

Truist analyst Srikripa Devarakonda views the recent weakness in Cytokinetics' stock as a buying opportunity and maintains a buy rating and $86 price target on the stock. Devarakonda continues to see Cytokinetics as a potential M&A target.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
47K Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    4953
    Followers
    0
    Following
    11K
    Visitors
    Follow

    Market Insights

    Market Hot Picks Market Hot Picks
    Unlock Now